QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer

NCT07286240 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Treatment of Recurrent Ovarian Cancer

Interventions

DRUG: QL1706 plus chemotherapy and anlotinib regimen

Sponsor

Affiliated Cancer Hospital & Institute of Guangzhou Medical University